Prediction of immunotherapy responsiveness in melanoma through single-cell sequencing-based characterization of the tumor immune microenvironment
Transl Oncol. 2024 Feb 27;43:101910. doi: 10.1016/j.tranon.2024.101910. Online ahead of print.ABSTRACTImmune checkpoint inhibitors (ICB) therapy have emerged as effective treatments for melanomas. However, the response of melanoma patients to ICB has been highly heterogenous. Here, by analyzing integrated scRNA-seq datasets from melanoma patients, we revealed significant differences in the TiME composition between ICB-resistant and responsive tissues, with resistant or responsive tissues characterized by an abundance of myeloid cells and CD8+ T cells or CD4+ T cell predominance, respectively. Among CD4+ T cells, CD4+ CXCL1...
Source: Translational Oncology - February 28, 2024 Category: Cancer & Oncology Authors: Yucheng Dong Zhizhuo Chen Fan Yang Jiaxin Wei Jiuzuo Huang Xiao Long Source Type: research
Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response- a translational research sub-study of the REZOLVE (ANZGOG-1101) clinical trial
CONCLUSION: Sufficient cfDNA was detected in both plasma and ascites to study three biomarkers. These samples can provide useful information and should be considered in the design of future ovarian cancer trials.PMID:38417292 | DOI:10.1016/j.tranon.2024.101914 (Source: Translational Oncology)
Source: Translational Oncology - February 28, 2024 Category: Cancer & Oncology Authors: Bonnita Werner Katrin M Sjoquist David Espinoza Sonia Yip Garry Chang Michelle M Cummins Linda Mileshkin Sumitra Ananda Catherine Shannon Michael Friedlander Kristina Warton Caroline E Ford Source Type: research
Prediction of immunotherapy responsiveness in melanoma through single-cell sequencing-based characterization of the tumor immune microenvironment
Transl Oncol. 2024 Feb 27;43:101910. doi: 10.1016/j.tranon.2024.101910. Online ahead of print.ABSTRACTImmune checkpoint inhibitors (ICB) therapy have emerged as effective treatments for melanomas. However, the response of melanoma patients to ICB has been highly heterogenous. Here, by analyzing integrated scRNA-seq datasets from melanoma patients, we revealed significant differences in the TiME composition between ICB-resistant and responsive tissues, with resistant or responsive tissues characterized by an abundance of myeloid cells and CD8+ T cells or CD4+ T cell predominance, respectively. Among CD4+ T cells, CD4+ CXCL1...
Source: Translational Oncology - February 28, 2024 Category: Cancer & Oncology Authors: Yucheng Dong Zhizhuo Chen Fan Yang Jiaxin Wei Jiuzuo Huang Xiao Long Source Type: research
Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response- a translational research sub-study of the REZOLVE (ANZGOG-1101) clinical trial
CONCLUSION: Sufficient cfDNA was detected in both plasma and ascites to study three biomarkers. These samples can provide useful information and should be considered in the design of future ovarian cancer trials.PMID:38417292 | DOI:10.1016/j.tranon.2024.101914 (Source: Translational Oncology)
Source: Translational Oncology - February 28, 2024 Category: Cancer & Oncology Authors: Bonnita Werner Katrin M Sjoquist David Espinoza Sonia Yip Garry Chang Michelle M Cummins Linda Mileshkin Sumitra Ananda Catherine Shannon Michael Friedlander Kristina Warton Caroline E Ford Source Type: research
Prediction of immunotherapy responsiveness in melanoma through single-cell sequencing-based characterization of the tumor immune microenvironment
Transl Oncol. 2024 Feb 27;43:101910. doi: 10.1016/j.tranon.2024.101910. Online ahead of print.ABSTRACTImmune checkpoint inhibitors (ICB) therapy have emerged as effective treatments for melanomas. However, the response of melanoma patients to ICB has been highly heterogenous. Here, by analyzing integrated scRNA-seq datasets from melanoma patients, we revealed significant differences in the TiME composition between ICB-resistant and responsive tissues, with resistant or responsive tissues characterized by an abundance of myeloid cells and CD8+ T cells or CD4+ T cell predominance, respectively. Among CD4+ T cells, CD4+ CXCL1...
Source: Translational Oncology - February 28, 2024 Category: Cancer & Oncology Authors: Yucheng Dong Zhizhuo Chen Fan Yang Jiaxin Wei Jiuzuo Huang Xiao Long Source Type: research
Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response- a translational research sub-study of the REZOLVE (ANZGOG-1101) clinical trial
CONCLUSION: Sufficient cfDNA was detected in both plasma and ascites to study three biomarkers. These samples can provide useful information and should be considered in the design of future ovarian cancer trials.PMID:38417292 | DOI:10.1016/j.tranon.2024.101914 (Source: Translational Oncology)
Source: Translational Oncology - February 28, 2024 Category: Cancer & Oncology Authors: Bonnita Werner Katrin M Sjoquist David Espinoza Sonia Yip Garry Chang Michelle M Cummins Linda Mileshkin Sumitra Ananda Catherine Shannon Michael Friedlander Kristina Warton Caroline E Ford Source Type: research
Prediction of immunotherapy responsiveness in melanoma through single-cell sequencing-based characterization of the tumor immune microenvironment
Transl Oncol. 2024 Feb 27;43:101910. doi: 10.1016/j.tranon.2024.101910. Online ahead of print.ABSTRACTImmune checkpoint inhibitors (ICB) therapy have emerged as effective treatments for melanomas. However, the response of melanoma patients to ICB has been highly heterogenous. Here, by analyzing integrated scRNA-seq datasets from melanoma patients, we revealed significant differences in the TiME composition between ICB-resistant and responsive tissues, with resistant or responsive tissues characterized by an abundance of myeloid cells and CD8+ T cells or CD4+ T cell predominance, respectively. Among CD4+ T cells, CD4+ CXCL1...
Source: Translational Oncology - February 28, 2024 Category: Cancer & Oncology Authors: Yucheng Dong Zhizhuo Chen Fan Yang Jiaxin Wei Jiuzuo Huang Xiao Long Source Type: research
Loss of p53 epigenetically modulates epithelial to mesenchymal transition in colorectal cancer
Transl Oncol. 2024 Feb 26;43:101848. doi: 10.1016/j.tranon.2023.101848. Online ahead of print.ABSTRACTEpithelial to Mesenchymal transition (EMT) drives cancer metastasis and is governed by genetic and epigenetic alterations at multiple levels of regulation. It is well established that loss/mutation of p53 confers oncogenic function to cancer cells and promotes metastasis. Though transcription factors like ZEB1, SLUG, SNAIL and TWIST have been implied in EMT signalling, p53 mediated alterations in the epigenetic machinery accompanying EMT are not clearly understood. This work attempts to explore epigenetic signalling during...
Source: Translational Oncology - February 27, 2024 Category: Cancer & Oncology Authors: Shreya Sharma Harsha Rani Yeshwanth Mahesh Mohit Kumar Jolly Jagannath Dixit Vijayalakshmi Mahadevan Source Type: research
The highly selective and oral phosphoinositide 3-kinase delta (PI3K- δ) inhibitor roginolisib induces apoptosis in mesothelioma cells and increases immune effector cell composition
Transl Oncol. 2024 Feb 26;43:101857. doi: 10.1016/j.tranon.2023.101857. Online ahead of print.ABSTRACTTargeting aberrantly expressed kinases in malignant pleural mesothelioma (MPM) is a promising therapeutic strategy. We here investigated the effect of the novel and highly selective Phosphoinositide 3-kinase delta (PI3K-δ) inhibitor roginolisib (IOA-244) on MPM cells and on the immune cells in MPM microenvironment. To this aim, we analyzed the expression of PI3K-δ by immunohistochemistry in specimens from primary MPM, cell viability and death in three different MPM cell lines treated with roginolisib alone and in combina...
Source: Translational Oncology - February 27, 2024 Category: Cancer & Oncology Authors: Claudia Kalla German Ott Francesca Finotello Karolina Niewola-Staszkowska Giusy Di Conza Michael Lahn Lars van der Veen Julia Sch üler Roger Falkenstern-Ge Joanna Kopecka Chiara Riganti Source Type: research
Comprehensive analysis and experimental verification of the mechanism of action of T cell-mediated tumor-killing related genes in Colon adenocarcinoma
CONCLUSION: Our research findings established a new gene signature for COAD. This gene signature helps to accurately stratify the risk of COAD patients and improve the current status of individualized care.PMID:38412662 | DOI:10.1016/j.tranon.2024.101918 (Source: Translational Oncology)
Source: Translational Oncology - February 27, 2024 Category: Cancer & Oncology Authors: Jing Chen Zhengfang Wang Qin Zhu Shiqi Ren Yanhua Xu Guangzhou Wang Lin Zhou Source Type: research
Preclinical evaluation of engineered L-asparaginase variants to improve the treatment of Acute Lymphoblastic Leukemia
CONCLUSION: EcA variants demonstrated better pharmacological properties compared to WT that makes them good candidates for further development.PMID:38412663 | DOI:10.1016/j.tranon.2024.101909 (Source: Translational Oncology)
Source: Translational Oncology - February 27, 2024 Category: Cancer & Oncology Authors: Soumika Sengupta Mainak Biswas Khushboo A Gandhi Saurabh Kumar Gupta Poonam B Gera Vikram Gota Avinash Sonawane Source Type: research
XIAP overexpressing inflammatory breast cancer patients have high infiltration of immunosuppressive subsets and increased TNFR1 signaling targetable with Birinapant
CONCLUSION: Using immunophenotyping and gene expression analysis in patient biospecimens along with in silico modeling and a preclinical model with a pan-IAP antagonist, this study revealed an interplay between increased TAMs, TNF-α signaling, and XIAP activation during (immune) stress in IBC. These data demonstrate the potential of IAP antagonists as immunomodulators for improving IBC therapeutic regimens.PMID:38412664 | DOI:10.1016/j.tranon.2024.101907 (Source: Translational Oncology)
Source: Translational Oncology - February 27, 2024 Category: Cancer & Oncology Authors: Christophe Van Berckelaer Steven Van Laere Seayoung Lee Michael A Morse Joseph Geradts Luc Dirix Mark Kockx Fran çois Bertucci Peter Van Dam Gayathri R Devi Source Type: research
Loss of p53 epigenetically modulates epithelial to mesenchymal transition in colorectal cancer
Transl Oncol. 2024 Feb 26;43:101848. doi: 10.1016/j.tranon.2023.101848. Online ahead of print.ABSTRACTEpithelial to Mesenchymal transition (EMT) drives cancer metastasis and is governed by genetic and epigenetic alterations at multiple levels of regulation. It is well established that loss/mutation of p53 confers oncogenic function to cancer cells and promotes metastasis. Though transcription factors like ZEB1, SLUG, SNAIL and TWIST have been implied in EMT signalling, p53 mediated alterations in the epigenetic machinery accompanying EMT are not clearly understood. This work attempts to explore epigenetic signalling during...
Source: Translational Oncology - February 27, 2024 Category: Cancer & Oncology Authors: Shreya Sharma Harsha Rani Yeshwanth Mahesh Mohit Kumar Jolly Jagannath Dixit Vijayalakshmi Mahadevan Source Type: research
The highly selective and oral phosphoinositide 3-kinase delta (PI3K- δ) inhibitor roginolisib induces apoptosis in mesothelioma cells and increases immune effector cell composition
Transl Oncol. 2024 Feb 26;43:101857. doi: 10.1016/j.tranon.2023.101857. Online ahead of print.ABSTRACTTargeting aberrantly expressed kinases in malignant pleural mesothelioma (MPM) is a promising therapeutic strategy. We here investigated the effect of the novel and highly selective Phosphoinositide 3-kinase delta (PI3K-δ) inhibitor roginolisib (IOA-244) on MPM cells and on the immune cells in MPM microenvironment. To this aim, we analyzed the expression of PI3K-δ by immunohistochemistry in specimens from primary MPM, cell viability and death in three different MPM cell lines treated with roginolisib alone and in combina...
Source: Translational Oncology - February 27, 2024 Category: Cancer & Oncology Authors: Claudia Kalla German Ott Francesca Finotello Karolina Niewola-Staszkowska Giusy Di Conza Michael Lahn Lars van der Veen Julia Sch üler Roger Falkenstern-Ge Joanna Kopecka Chiara Riganti Source Type: research
Comprehensive analysis and experimental verification of the mechanism of action of T cell-mediated tumor-killing related genes in Colon adenocarcinoma
CONCLUSION: Our research findings established a new gene signature for COAD. This gene signature helps to accurately stratify the risk of COAD patients and improve the current status of individualized care.PMID:38412662 | DOI:10.1016/j.tranon.2024.101918 (Source: Translational Oncology)
Source: Translational Oncology - February 27, 2024 Category: Cancer & Oncology Authors: Jing Chen Zhengfang Wang Qin Zhu Shiqi Ren Yanhua Xu Guangzhou Wang Lin Zhou Source Type: research
